Stifel reiterates Buy on Crescent Biopharma stock, $28 target
Stifel maintained a Buy rating and $28 target on Crescent Biopharma (NASDAQ:CBIO) after FDA clearance of its CR-002 drug. The stock trades at $13.94, down 28% in six months. Stifel expects trial data in 2027. Crescent raised $143.7M in a public offering. H.C. Wainwright upgraded CBIO to Buy with a $36 target.
How this was made
The 30-second read
Why it matters
The FDA IND clearance for CR-002 is a catalyst that could lift CBIO ahead of Phase 1/2 data expected in H2 2027, supporting Stifel's higher price target.
Market read
Regulatory approval for a small‑cap biotech often triggers short‑term price appreciation and increased analyst coverage.
What to watch
Potential competition from Henlius and Pfizer ADCs and the need for substantial data to justify the valuation.
Background
Crescent Biopharma recently completed a $143.7 million public offering, strengthening its balance sheet for upcoming trials.
Ticker impact
Stifel reiterated a Buy rating and raised the price target to $28 after the FDA cleared Crescent Biopharma's IND for CR-002, a new clinical asset.
upward pressure as investors price in the upcoming Phase 1/2 data and the higher target
Regulatory approval is a material event for a biotech; the new $28 target implies ~50% upside from current levels.
Market effects
Positive for the broader oncology ADC sector as FDA clearance may boost confidence in similar pipelines.
U.S. biotech market may see modest gains from the news.
Limited to investors focused on U.S. biotech and specialty pharma.
Counterpoint
If the upcoming trial data disappoint, the stock could face a sharp correction despite the clearance.
Key entities
- AnalystStifel
Maintained Buy rating and set $28 target.
- RegulatorFDA
Cleared IND for CR-002.
